Description

Revvity: From China Exit to SaaS Momentum—A Strategic Reset Taking Shape!

Revvity reported first quarter 2026 results demonstrating 3% total company organic growth alongside adjusted operating margins of 23.6%, exceeding their earlier outlook. Adjusted earnings per share came in at $1.06, surpassing guidance by a modest margin. The company’s Life Sciences segment grew 3% organically, driven by low single-digit growth in reagents and mid-single-digit growth in instrumentation, while the Diagnostics segment grew 4% organically, bolstered by strong double-digit growth in Reproductive Health and stable performance in Immunodiagnostics outside China. However, Immunodiagnostics in China faced low single-digit organic declines, consistent with expected policy-driven headwinds and resulting in a double-digit decline in the region overall. A strategic decision to divest the China Immunodiagnostics business, which contributed about 6% of revenue in 2025, was highlighted as a key transformative step. The market’s structural challenges, including regulatory and manufacturing localization requirements, led the company to focus resources on higher-growth, higher-margin areas.